Experience

To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.

Filters

Emirate of Abu Dhabi $5 billion notes offering

Davis Polk advised the joint lead managers in connection with a Rule 144A/Regulation S offering by the Emirate of Abu Dhabi of $2 billion aggregate principal amount of 0.750% notes due 2023…

Royalty Pharma $6 billion senior notes offering

Davis Polk advised Royalty Pharma plc in connection with its Rule 144A/Regulation S offering of $1 billion aggregate principal amount of its 0.75% senior notes due 2023, $1 billion…

SEB $2 billion notes offering

Davis Polk advised the joint book-running managers on the Rule 144A/Regulation S offering by SEB of $1 billion aggregate principal amount of 0.550% notes due 2023, $600 million…

Cellnex Telecom €4 billion equity offering

Davis Polk advised Cellnex Telecom, S.A. as to U.S. law in connection with its offering of 101,382,140 new ordinary shares pursuant to a public rights offering in Spain and private…

CureVac $245.3 million IPO

Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which includes 1,999,999 common shares from the full exercise of the…

Linde $1 billion notes offering

Davis Polk advised the underwriters on the registered offering of $700 million aggregate principal amount of 1.100% notes due 2030 and $300 million aggregate principal amount of 2.000%…

Tigermed HK$10.7 billion IPO and Hong Kong listing

Davis Polk advised Hangzhou Tigermed Consulting Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in…
Back to top